Company Overview and News

 
NANOBIOTIX half year results for the six months ended June 30, 2018

2018-09-04 globenewswire
Paris, France and Cambridge, Massachusetts, USA, September 4, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018.
NANO

 
NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment Bank

2018-07-26 globenewswire
Paris, France and Cambridge, Massachusetts, July 26, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities.
NANO

 
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3

2018-06-21 globenewswire
Paris, France and Cambridge, Massachusetts, June 21, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS).
NANO

 
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

2018-05-03 globenewswire
NANOBIOTIX PARTNERS WITH WEILL CORNELL MEDICINE ON PRE-CLINICAL STUDIES TO EVALUATE THE IMPACT OF NBTXR3 ON cGAS-STING PATHWAY IN MAMMARY CANCERS
NANO

 
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

2018-04-17 globenewswire
AACR ANNUAL MEETING 2018: NANOBIOTIX PRESENTED PRECLINICAL DATA SHOWING NBTXR3 NANOPARTICLES CAN ACTIVATE THE cGAS-STING PATHWAY
NANO

 
NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB

2018-04-10 globenewswire
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB
NANO

 
NANOBIOTIX : Nanobiotix 2017 Annual Results

2018-03-30 globenewswire
Paris, France and Cambridge, Massachusetts, USA, March 30, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017:
NANO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EPA:NANO / NANOBIOTIX on message board site Silicon Investor.

NanoViricides - Nanobiotechnology NanoViricides - Nanobiotechnology NanoViricides - Nanobiotechnology NNVC - NanoViricides, Inc. NNVC - NanoViricides, Inc. NNVC - NanoViricides, Inc.
Nanoviricides - The Other Board Nanoviricides - The Other Board Nanoviricides - The Other Board NNLX - NanoLogix, Incorporated NNLX - NanoLogix, Incorporated NNLX - NanoLogix, Incorporated
NANO NANO NANO NNVC - NanoViricides, Inc. (Bulls Board) NNVC - NanoViricides, Inc. (Bulls Board) NNVC - NanoViricides, Inc. (Bulls Board)
PanaceaNano PanaceaNano PanaceaNano Nano One Materials Corp. Nano One Materials Corp. Nano One Materials Corp.
NanoViricides Professional NanoViricides Professional NanoViricides Professional NanoTech Entertainment (OTCPINK:NTEK) NanoTech Entertainment (OTCPINK:NTEK) NanoTech Entertainment (OTCPINK:NTEK)